Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

Key Clinical Message We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical case reports 2018-04, Vol.6 (4), p.634-637
Hauptverfasser:	Alderuccio, Juan Pablo, Desai, Amrita, Yepes, Monica M., Chapman, Jennifer R., Vega, Francisco, Lossos, Izidore S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast implant‐associated anaplastic large‐cell lymphoma and brentuximab vedotin Case Report Case Reports Immunotherapy Monoclonal antibodies non‐Hodgkin's lymphoma Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!